The new paradigm in TB treatment focuses on using existing drugs and evaluating them in combination to develop better, shorter regimens.

An open letter from civil society, academics and experts supports a number of proposed reforms in the Draft National Policy on Intellectual Property, and offers specific recommendations for further improvements.

2013 International Union Against TB and Lung Disease World Conference
Date: 1 November 2013
Time: 18h00 - 22h00
Location: Hôtel Concorde La Fayette, Batignolles/Longchamp Room, 3, Place du Général Koenig, 75850 Paris Cedex 17

Cost to end deaths from childhood TB estimated to be at least US$120 million annually.

The publication is intended for all health care workers involved in preventing, diagnosing, treating and caring for people living with TB and HIV in the specific settings of the WHO European Region.

A resource for the continued implementation of the Consolidated Action Plan to Prevent and Combat Multidrug- and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011–2015.

A review of medicines to treat TB, including both existing products and emerging technologies with the potential to improve treatment.

The World Health Organization, The Union, the Stop TB Partnership, USAID, CDC, the Treatment Action Group and UNICEF will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.

Largest ever roll-out of GeneXpert® rapid TB test machines in 21 countries will help halt spread of drug-resistant TB and save 62,000 lives.

Trade & Industry’s draft IP policy lays foundation to prevent abusive patents from blocking access to affordable medicines.